<DOC>
	<DOCNO>NCT02920125</DOCNO>
	<brief_summary>To evaluate benefit Ayurvedic SUVED &amp; REIMMUGEN Colostrum reduction/reversal symptom study clinical progress Vascular disease ; CAD , CAV , Stroke , DVT patient .</brief_summary>
	<brief_title>Study Clinical Outcome Ayurvedic SUVED Reimmugen ( Colostrum ) , Patients Vascular Disease</brief_title>
	<detailed_description>Aim : A non-invasive , effective , compatible , Integrative treatment option address grow burden Vascular disease ; Importance : Ayurvedic SUVED ( cardio tonic , continuous clotlysis , endothelial repair , powerful rejuvenator , antioxidant ) Reimmugen ( Cow Colostrum - IgG , GF ) provide sustained Functional , symptomatic relief clinical report regression disease . No adverse interaction report . Application : Addition SUVED &amp; REIMMUGEN help : - Acute MI , Thrombotic stroke , DVT , hasten symptomatic recovery , reduce hospitalization time , mortality , help dissolve clot / soft thrombus ; reversal atherosclerotic plaque ; improve functional life - Improvements Cardiac Function : LVEF ; Global perfusion - Rejuvenation endothelium , vascular function . - Improved physical strength : digestion ; GI function ; immunity ; accelerate internal heal - Secondary prevention avoid incidences post event treatment . Health condition/problem study Vascular disease , esp CVA , IHD , CAD , DVT , PAD Volunteers take OPD IPD SKNMC &amp; GH prior consent participation . Intervention Medicament base give addition conventional ongoing therapy guidance SKNMC doctor . Study type Clinical trial : Double Blind placebo control trial . Interventional Trial : regular treatment . Evaluation additional Integrative esp Ayurvedic medicament clinical functional outcome . Intervention comparator agent 1 . Ayurvedic ghana formulation name SUVED . 2 . Whole Cow Colostrum call Reimmugen These give period three month addition ongoing medication study additional benefit patient functional clinical investigation . The control intervention/s is/are intervention study intervention evaluate double blind placebo . Suved 1 BD 3 month Reimmugen 1 TDS 3 month In acute case Suved 1 TDS Reimmugen 2 TDS 3 month . Inclusion/ Exclusion criterion Inclusion criterion Adult male female diagnosis Vascular disease lead IHD , CAD , CVA , DVT , PAD stage . Exclusion Criteria : Pregnant lactate woman , Patients age 18 Acute IPD operative condition Patients undergoing interventional procedure / surgical treatment Vascular disease ; discharge intensive care ; Haemorrhagic cerebro vascular stroke .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<criteria>Adult male female diagnosis Vascular disease lead IHD , CAD , CVA , DVT , PAD stage Pregnant lactate woman Patients age 18 Acute IPD operative condition Patients undergo intervention procedure / surgical treatment Vascular disease ; discharge intensive care ; Hemorrhagic cerebro vascular stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vascular disease</keyword>
</DOC>